Concepedia

Anita Kohli

AK

Statistics

Publications

59

Citations

7.5K

H-Index

33

Active since

2002

Affiliations

Gilead Sciences (United States)(Current)

National Institute of Allergy and Infectious Diseases

University of Maryland, Baltimore

National Institutes of Health

Arizona Liver Health

Anita Kohli is an author at Gilead Sciences (United States) specializing in infectious diseases, pharmacotherapy, and antiviral therapy.

ORCID

Publications per year

2002–2025

59

Publications

59

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

David M. Weinreich, Sumathi Sivapalasingam, Thomas Norton et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text

, , +16

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

, , +8

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

, , +12

Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics

A. Osinusi, Eric G. Meissner, Y.-J. Lee et al. · JAMA · 2013 · 287 citations

, , +17

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Rohit Loomba, Mazen Noureddin, Kris V. Kowdley et al. · Hepatology · 2020 · 278 citations

, , +17

1–5 of 59